ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,496Medicare Part D Prescriptions Filled, Including Refills

Rank: 167 out of 2094

$1.05M Total Retail Price of All Prescriptions

Rank: 83 out of 2094

291 Patients Receiving at Least One Drug in Part D
57%Patients 65 Years and Older
90% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Jersey
Lower avg

Schedule Two
Controlled Substances

27% of this provider’s 291 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

1% of this provider’s 5,447 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

37% of this provider’s prescriptions were for brand-name drugs, compared to an average of 32%.

Prescription Price

$100 was the average price of a prescription from this provider, compared to $78 among peers.

Prescriptions per Patient

36 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Jersey
AMLODIPINE BESYLATE 323 204 1 2
OXYCODONE HCL 311 72 S2 2 63
ZOLPIDEM TARTRATE 263 136 3 14
SIMVASTATIN 246 177 4 1
OMEPRAZOLE 245 170 5 4
ENDOCET 236 75 S2 6 88
CRESTOR 185 99 7 15
METFORMIN HCL 167 109 8 8
LEVOTHYROXINE SODIUM 167 112 8 3
LOVAZA 163 102 10 53
CLOPIDOGREL 152 96 11 22
FUROSEMIDE 149 57 12 6
GABAPENTIN 136 83 13 23
PROAIR HFA 133 58 14 45
WARFARIN SODIUM 130 91 15 11
NEXIUM 117 73 16 16
LISINOPRIL 117 35 16 7
JANUVIA 113 77 18 35
PLAVIX 110 67 19 38
LANTUS SOLOSTAR 107 52 20 76
SINGULAIR 103 49 21 64
CARVEDILOL 102 64 22 19
CLONIDINE HCL 100 32 23 62
GLIPIZIDE XL 99 57 24 122
TAMSULOSIN HCL 98 61 25 29
ALENDRONATE SODIUM 94 56 26 30
ONGLYZA 91 65 27 134
DIOVAN 88 56 28 13
HYDROCHLOROTHIAZIDE 85 55 29 12
LEVOFLOXACIN 84 28 30 70
KOMBIGLYZE XR 83 46 31 248
METOPROLOL TARTRATE 81 50 32 10
CLOTRIMAZOLE-BETAMETHASONE 79 41 33 91
DOXYCYCLINE HYCLATE 76 31 34 187
FENOFIBRATE 72 40 35 104
AMLODIPINE BESYLATE-BENAZEPRIL 70 54 36 58
ATORVASTATIN CALCIUM 69 47 37 5
AVELOX 68 42 38 300
LACTULOSE 66 23 39 65
DIOVAN HCT 65 28 40 28
AMOX TR-POTASSIUM CLAVULANATE 64 26 41 107
ENALAPRIL MALEATE 63 30 42 25
SPIRONOLACTONE 62 36 43 93
METOCLOPRAMIDE HCL 62 35 43 141
VIREAD 60 11 45 366
TIZANIDINE HCL 58 13 46 254
NAMENDA 58 41 46 32
LABETALOL HCL 58 32 46 215
IBUPROFEN 57 0 49 73
GLIPIZIDE ER 56 42 50 126
METRONIDAZOLE 55 26 51 290
SPIRIVA 55 11 51 60
MONTELUKAST SODIUM 52 21 53 128
FAMOTIDINE 52 25 53 34
ADVAIR DISKUS 52 14 53 36
FENTANYL 51 0 S2 56 68
PREDNISONE 50 24 57 54
CYCLOBENZAPRINE HCL 50 12 R 57 115
AVODART 50 34 57 163
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 22, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.